Last SFr.117.30 CHF
Change Today +4.60 / 4.08%
Volume 506.9K
ATLN On Other Exchanges
SIX Swiss Ex
As of 11:43 AM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

actelion ltd-reg (ATLN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/10/14 - SFr.118.00
52 Week Low
12/19/13 - SFr.71.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACTELION LTD-REG (ATLN)

Related News

No related news articles were found.

actelion ltd-reg (ATLN) Related Businessweek News

No Related Businessweek News Found

actelion ltd-reg (ATLN) Details

Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; Opsumit, an orally available endothelin receptor antagonist; and Valchlor, a chemotherapeutic agent for the treatment of mycosis fungoides, a common type of cutaneous T-cell lymphoma. The company also provides Veletri, a formulation of epoprostenol for the treatment of PAH; Ventavis, an inhaled formulation of iloprost for the treatment of PAH; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Japan, China, Russia, and Mexico. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

2,400 Employees
Last Reported Date: 10/21/14
Founded in 1997

actelion ltd-reg (ATLN) Top Compensated Officers

Founder, Chief Executive Officer, Member of M...
Total Annual Compensation: SFr.2.6M
Compensation as of Fiscal Year 2013.

actelion ltd-reg (ATLN) Key Developments

Actelion Selects Avella Specialty Pharmacy to Distribute VALCHLOR

Avella Specialty Pharmacy announced that is has been chosen by Actelion as an additional specialty pharmacy authorized to dispense VALCHLOR ®, the first FDA-approved topical gel formulation of mechlorethamine. VALCHLOR has been approved for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Avella will work with dermatology providers and their patients on advanced patient services including prior authorization assistance, securing financial support for patients who qualify and dosing adjustments, if needed.

TTPH Reportedly Explores Options For Sale

Tetraphase Pharmaceuticals, Inc. (NasdaqGS:TTPH) is exploring a sale after attracting interest from potential buyers, people familiar with the matter said. TTPH is working with advisers to explore its options, the people said, asking not to be identified because the deliberations are private. TTPH may attract interest from bidders including Actelion Ltd. (SWX:ATLN) and Roche Holding AG (SWX:ROG), the people said. A spokesman for Tetraphase declined to comment. Representatives for Actelion and Roche couldn’t immediately be reached to comment outside of normal business hours.

Actelion Ltd. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 10:00 AM

Actelion Ltd. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 10:00 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATLN:VX SFr.117.30 CHF +4.60

ATLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $91.83 USD +4.62
Ipsen SA €41.89 EUR +0.075
Meda AB kr109.80 SEK +1.60
UCB SA €65.02 EUR +1.62
United Therapeutics Corp $131.11 USD +3.61
View Industry Companies

Industry Analysis


Industry Average

Valuation ATLN Industry Range
Price/Earnings 18.1x
Price/Sales 6.3x
Price/Book 6.3x
Price/Cash Flow 16.3x
TEV/Sales 5.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTELION LTD-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at